Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dexcom Inc (NQ: DXCM )

69.96 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dexcom Inc

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
31 32 Next >
NASDAQ:DXCM: a strong growth stock preparing for the next leg up?.
DEXCOM INC (NASDAQ:DXCM)—Positioned as a High-Growth Stock, Ready for a Potential Breakout. 
Via Chartmill
Evaluating NASDAQ:DXCM for Growth Investment Opportunities.
Why the growth investor may take a look at NASDAQ:DXCM. 
Via Chartmill
These 2 Growth Stocks Are Brilliant Buys for the New Year
Business is booming for these stocks, and investors might want to stop and take note. 
Via The Motley Fool
Dexcom Schedules Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call for February 8, 2024 at 4:30 p.m. Eastern Time
From DexCom, Inc.
Via Business Wire
Expert Ratings For DexCom
Via Benzinga
Here's How Much $1000 Invested In DexCom 15 Years Ago Would Be Worth Today
Via Benzinga
A Closer Look at DexCom's Options Market Dynamics
Via Benzinga
Is NASDAQ:DXCM a Fit for Growth Investing Strategies?
Should you consider DEXCOM INC (NASDAQ:DXCM) for growth investing? 
Via Chartmill
Don't overlook NASDAQ:DXCM—a stock with solid growth prospects and a reasonable valuation.
Investors should take note ofDEXCOM INC (NASDAQ:DXCM), a growth stock that remains attractively priced. 
Via Chartmill
MarketBeat ‘Stock of the Week’: Intuitive Surgical hits new highs
With recent obesity drug fears proving to be overblown and equipment placements growing, expect ISRG to reward growth investors with plenty more record highs. 
Via MarketBeat
Topics Earnings
Exposures Financial
3 Mid-Cap Stocks Poised for a Breakout in 2024
Mid-cap stocks are expected to have a breakout year especially in light of their underperformance in 2023 with these equities looking strong. 
Via InvestorPlace
The 3 Best Growth Stocks to Buy in January 2024
The best growth stocks to buy for 2024 with an impressive growth history and solid long-term tailwinds to support 30% EPS growth. 
Via InvestorPlace
Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review
The major indexes and leading stocks rebounded. Bitcoin ETFs fell in their debut. 
Via Investor's Business Daily
Topics ETFs
The Latest Analyst Ratings For DexCom
Via Benzinga
2 Growth Stocks That Could Make You Richer in 2024 and Beyond
Last year wasn't great for either stock, but that's no reason to ignore them. 
Via The Motley Fool
History Says the Nasdaq Will Soar in 2024: 1 Stock-Split AI Growth Stock to Buy Now and Hold Forever
Nvidia is well positioned to create value for patient shareholders, given its leadership in artificial intelligence chips. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Stocks to Capitalize on the Telehealth Explosion
These three telehealth stocks are leading the way for improved telehealth offerings, highlighted after the pandemic. 
Via InvestorPlace
Dexcom's Recent 66% Run Continues With A Breakout On Bullish Fourth-Quarter Sales
Dexcom beat fourth-quarter sales expectations and issued stronger-than-usual annual guidance. 
Via Investor's Business Daily
Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2023 and Initial 2024 Outlook
From DexCom, Inc.
Via Business Wire
DexCom Unusual Options Activity
Via Benzinga
Looking Into DexCom's Recent Short Interest
Via Benzinga
HCA Healthcare Rallies: Weight-loss drugs really a big threat?
HCA Healthcare rebounds amid concerns about weight-loss drugs' impact. The healthcare giant's revenue growth hints at resilience despite sector challenges. 
Via MarketBeat
Topics ETFs
Why NASDAQ:DXCM Is a Promising High-Growth Stock in the Midst of Consolidation.
Why DEXCOM INC (NASDAQ:DXCM) Is a Standout High-Growth Stock in a Consolidation Phase. 
Via Chartmill
1 Stock-Split Stock to Buy Hand Over Fist in 2024 and 1 to Avoid
Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there's a historically cheap outperformer that's ripe for the picking, as well as an... 
Via The Motley Fool
For those who appreciate growth without the sticker shock, NASDAQ:DXCM is worth considering.
NASDAQ:DXCM stands out as a growth opportunity that won't break the bank. 
Via Chartmill
These 3 Companies Can Be the Next Stock-Split Stocks in 2024
Since mid-2021, Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk have conducted stock splits. Three well-known companies look set to follow in... 
Via The Motley Fool
$100 Invested In This Stock 15 Years Ago Would Be Worth $21,000 Today
Via Benzinga
DexCom's Options Frenzy: What You Need to Know
Via Benzinga
Meet the Stock-Split Stock Warren Buffett Is Likeliest to Buy in 2024
Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there's a stock-split stock that checks all the right boxes for the Oracle of Omaha. 
Via The Motley Fool
3 Stock-Split Stocks Billionaires Are Piling Into Ahead of 2024
Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there are three industry leaders Wall Street's brightest money managers want to own for... 
Via The Motley Fool
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.